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Sulphites, such as sodium bisulphite and sodium metabi-
sulphite, are widely used as antioxidants or preservatives 
in a wide range of substances, such as food, cosmetics 
and medications (1). It has been reported that sulphite in-
take can cause systemic type I allergic reactions, such as 
urticaria (2) and anaphylaxis (3, 4). In addition, external 
application of sulphites can cause local type IV allergic 
reactions, such as contact dermatitis (1, 5). However, it 
is not known whether sulphite intake can cause systemic 
type IV allergic reactions. We describe here a case of 
drug eruption, thought to be a systemic type IV allergic 
reaction to sulphites, following a high-calorie infusion.
CASE REPORT
A 50-year-old woman was referred to our dermatology department 
because of a systemic skin eruption. She had been diagnosed with 
myasthenia gravis 10 years earlier. Because she had difficulty with 
food intake due to decreased bowel movement resulting from the 
myasthenia gravis, she had started a high-calorie infusion (Ami-
notripa 2® given 1,800 ml every 3 days [Otsuka Pharmaceutical 
Co. Ltd, Tokyo, Japan]) 10 days previously. Three days after the 
start of infusion, small red pruritic papules developed over most of 
the patient’s body (Fig. 1a, b). It was suspected that this symptom 
was indicative of a drug eruption. Because she had not changed 
any medications before the eruption, we suspected that Aminotripa 
2® was the cause. As topical steroid treatment did not improve the 
eruption, Aminotripa 2® was discontinued and changed to a sugar 
electrolyte maintenance transfusion. After stopping Aminotripa 2®, 
the eruption gradually disappeared. Aminotripa 2® is composed 
of amino acids, electrolytes, sugar, and some additives (sulphite, 
glacial acetic acid, and citric acid hydrate) available from: http://
www.kegg.jp/medicus-bin/japic_med_product?id=00055508. 
Among the ingredients, we focused on the sulphite (sodium bi-
sulphite) in the additives, because it has been reported that sodium 
bisulphites can cause allergic reactions, such as contact dermatitis 
(1) and anaphylaxis (3, 4). A 48-h closed patch test was performed 
with Finn Chambers® (Epitest Oy, Tuusula, Finland) on Scanpor 
tape® (Alpharma AS, Vennesla, Norway) for sodium bisulphite 
(0.1% and 1% in pet) (provided by Otsuka Pharmaceutical Co. 
Ltd), Aminotripa 2®, and Neoparen 2® (Otsuka Pharmaceutical 
Co. Ltd), another high-calorie infusion that contains a much lower 
concentration of sodium bisulifite (0.002%). The reactions were 
determined at 48 h and 72 h after application of 
the patch test, in accordance with the recommen-
dations of the International Contact Dermatitis 
Research Group (ICDRG). Although the patient 
was under treatment with predonisolone 10 mg/
day as treatment for myasthenia gravis, she exhi-
bited a positive reaction to 0.1% and 1% sodium 
bisulphite (Fig. 1b). She also reported pruritus 
at the Aminotripa 2® (containg 0.04% of sodium 
bisulphite) test site. She did not exhibit any po-
sitive reaction or report pruritus to Neoparen 2®. 
Based on these findings, we diagnosed the patient 
with a drug eruption due to sodium bisulphite in 
Aminotripa 2®. She resumed high-calorie infusion 
therapy using Neoparen 2®, and the skin eruption 
has not re-appeared.
DISCUSSION
To date, type IV allergic reations to 
sulphites have been reported only as 
contact dermatitis following the use of 
sulphite-containing ointments or cosme-
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Fig. 1. Clinical presentation. (a, b) Accumulation of 
red papules on (a) the right forearm and (b) the leg. (c) 
Seventy-two hours after the patch test. The reactions were 
classified according to International Contact Dermatitis 
Research Group (ICDRG) guidelines. Positive reactions 
(+) were detected for sodium bisulphite 1% and 0.1% pet.
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tics (1). However, the case described here suggests 
that sulphite intake could also cause a type IV allergic 
reaction leading to systemic eruption (systemic type 
IV allergic reaction).
Sulphites are frequently used as additives in a wide 
range of foods and medications. The amount of sul-
phites in food is kept below a certain level (for example, 
in Japan wine contains less than 0.35 g/kg of sulphites). 
However, the intake of various types of food containing 
sulphites would increase the total amount of sulphites 
consumed, and may cause a systemic type IV allergic 
reaction, as in the current case. In this context, sulphite 
allergy should be considered as a differential diagnosis 
of systemic eruption.
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